76  De Socio GV, Sgrelli A, Tosti A, Baldelli F. Severe acute hepatitis B treated with entecavir. Mediterr J Hematol Infect Dis 2011; 3: e2011010. Hepatitis delta virus (HDV) is a defective Selleck MK-8669 virus that is dependent on HBV for replication. It can appear as coinfection or superinfection with hepatitis B. We recommend all HBsAg-positive patients are tested for HDV antibody (1B). We suggest repeat testing for HDV-seronegative HBsAg-positive patients is required only if the patient has persistent risk factors (2D). We recommend all HDV-seropositive individuals should be tested for HDV RNA (1C). We recommend all HIV/HBV/HDV-infected patients with detectable HBV DNA be treated with tenofovir as part of, or in addition to, ART (1D).

We recommend all those with HDV RNA be considered for early treatment by a physician with experience in this condition. Proportion of chronic HBV-infected HIV patients who had an HDV antibody test In the UK, the reported prevalence of HDV among HBsAg-positive

patients ranges from 2.1 to 8.5% [1–3] and in those with HBV/HIV infection from 2.6 to 6.0% [2,4–5], which is lower than the prevalence of 14.5% reported from a European HIV cohort [6]. This observed variation is most likely due to differences in patient populations in terms of risk factors, countries of origin and disease severity. The two main risk factors associated with HDV are injection drug use (IDU) and origin from an HDV-endemic area, which includes Eastern and Southern Europe,

sub-Saharan Africa and the Amazon Basin of South America [7]. Due to successful strategies to prevent HBV infection in IDUs, the relative contribution see more of patients from HDV-endemic areas has increased. The usual screening test for HDV is total HDV antibody, using enzyme immunoassay, although this does not discriminate between active or past Etofibrate infection. HDV IgM has been used by some as a surrogate marker of disease activity [8–9]. However, a sensitive HDV RNA test is preferred to determine viral activity [8]. HDV RNA assays that can detect and quantify all clades of HDV are available in the UK in specialist hepatitis reference laboratories [10–11]. HDV superinfection frequently results in the suppression of replication of other hepatitis viruses [12–13]. It is therefore important to exclude HDV in every HBsAg-positive individual as the apparent suppression of HBV DNA may be incorrectly interpreted as indication of inactive liver disease. Patients with HDV superinfection are more likely to have severe hepatitis with progression of liver disease and development of cirrhosis and hepatocellular carcinoma [14–17]. Results of treatment outcome have mostly been obtained in HIV non-infected populations. A one year course of interferon therapy has been effective in sustaining a virological response in 28–41% of monoinfected patients [18–19]. Small case series with HIV-infected patients treated with pegylated interferon showed a similar outcome [20].